Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994696359> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2994696359 endingPage "S499" @default.
- W2994696359 startingPage "S499" @default.
- W2994696359 abstract "Randomized controlled trials and published guidelines recommend endocrine therapy, specifically cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) in combination with either aromatase inhibitors or fulvestrant, as first-line (1L) therapy for hormone receptor-positive (HR+) human epidermal receptor2 negative (HER2-) metastatic breast cancer (mBC). Chemotherapy is reserved for patients in visceral crisis. We aimed to understand the use of 1L chemotherapy in the treatment of HR+/HER2- mBC in the U.S. post-approval of the first CDK 4/6i palbociclib in 2015. Female HR+/HER2- patients diagnosed with mBC (at least one non-diagnostic inpatient/two outpatient claims for breast cancer and one claim for lymph node/distant metastatic disease) initiating 1L treatment between 01/01/2015 and 10/31/2018 were identified in the Symphony Health administrative claims database. Regimes received in 1L were categorized as: single-agent chemotherapy (saChemo), combination chemotherapy (cChemo), and hormonal/targeted (H/T). Patient demographics, frequency of use of agents, comorbidities (Charlson components) at 1L initiation, and the proportion of patients who had not initiated second-line (2L) therapy (proxy for progression-free survival) at 6 months from 1L start of treatment (Kaplan-Meier method) were assessed. 4317 HR+/HER- patients were identified. 1L treatment patterns/mean age: saChemo 18%/64yrs, cChemo 21%/61yrs, H/T 61%/67yrs. Comorbidities >2: saChem=6%, cChemo=4%, H/T=6%. Visceral metastasis: saChemo=23%, cChemo=19%, H/T=58%. The top 3 most frequent saChemo: capecitabine=12%, paclitaxel=11%, nab-paclitaxel=11%; cChemo: cyclophosphamide/doxorubicin=23%, cyclophosphamide/docetaxel=9%, carboplatin/paclitaxel=4%.; H/T: anastrozole=25%, letrozole=23%, fulvestrant=13%. 6-month proportion of patients not initiating 2L, saChemo: paclitaxel=94%, capecitabine=76%, docetaxel=60%; cChemo: carboplatin/nab-paclitaxel=86%, carboplatin/paclitaxel=84%, carboplatin/docetaxel=74%; H/T: letrozole/palbociclib=89%, letrozole=84%, anastrozole=82%. Endocrine therapy is recommended by the NCCN guidelines as the treatment of choice for HR+/HER2- patients. However, chemotherapy still constitutes >40% of 1L choices since the introduction of CDK4/6i. More alarming is the continued use of cChemo for these patients. Further long term follow-up is needed to understand median time to next treatment (proxy for progression-free survival)." @default.
- W2994696359 created "2019-12-26" @default.
- W2994696359 creator A5002637102 @default.
- W2994696359 creator A5006893148 @default.
- W2994696359 creator A5013664932 @default.
- W2994696359 creator A5038056134 @default.
- W2994696359 creator A5050866878 @default.
- W2994696359 date "2019-11-01" @default.
- W2994696359 modified "2023-09-30" @default.
- W2994696359 title "PCN325 REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS: DIVERGENCE FROM EVIDENCE-BASED MEDICINE" @default.
- W2994696359 doi "https://doi.org/10.1016/j.jval.2019.09.520" @default.
- W2994696359 hasPublicationYear "2019" @default.
- W2994696359 type Work @default.
- W2994696359 sameAs 2994696359 @default.
- W2994696359 citedByCount "0" @default.
- W2994696359 crossrefType "journal-article" @default.
- W2994696359 hasAuthorship W2994696359A5002637102 @default.
- W2994696359 hasAuthorship W2994696359A5006893148 @default.
- W2994696359 hasAuthorship W2994696359A5013664932 @default.
- W2994696359 hasAuthorship W2994696359A5038056134 @default.
- W2994696359 hasAuthorship W2994696359A5050866878 @default.
- W2994696359 hasBestOaLocation W29946963591 @default.
- W2994696359 hasConcept C121608353 @default.
- W2994696359 hasConcept C126322002 @default.
- W2994696359 hasConcept C143998085 @default.
- W2994696359 hasConcept C2775930923 @default.
- W2994696359 hasConcept C2776387010 @default.
- W2994696359 hasConcept C2776694085 @default.
- W2994696359 hasConcept C2776755627 @default.
- W2994696359 hasConcept C2777176818 @default.
- W2994696359 hasConcept C2777802072 @default.
- W2994696359 hasConcept C2777909004 @default.
- W2994696359 hasConcept C2778239845 @default.
- W2994696359 hasConcept C2778812593 @default.
- W2994696359 hasConcept C2779744173 @default.
- W2994696359 hasConcept C2780482068 @default.
- W2994696359 hasConcept C2780835546 @default.
- W2994696359 hasConcept C2781190966 @default.
- W2994696359 hasConcept C2781451048 @default.
- W2994696359 hasConcept C526805850 @default.
- W2994696359 hasConcept C530470458 @default.
- W2994696359 hasConcept C71924100 @default.
- W2994696359 hasConceptScore W2994696359C121608353 @default.
- W2994696359 hasConceptScore W2994696359C126322002 @default.
- W2994696359 hasConceptScore W2994696359C143998085 @default.
- W2994696359 hasConceptScore W2994696359C2775930923 @default.
- W2994696359 hasConceptScore W2994696359C2776387010 @default.
- W2994696359 hasConceptScore W2994696359C2776694085 @default.
- W2994696359 hasConceptScore W2994696359C2776755627 @default.
- W2994696359 hasConceptScore W2994696359C2777176818 @default.
- W2994696359 hasConceptScore W2994696359C2777802072 @default.
- W2994696359 hasConceptScore W2994696359C2777909004 @default.
- W2994696359 hasConceptScore W2994696359C2778239845 @default.
- W2994696359 hasConceptScore W2994696359C2778812593 @default.
- W2994696359 hasConceptScore W2994696359C2779744173 @default.
- W2994696359 hasConceptScore W2994696359C2780482068 @default.
- W2994696359 hasConceptScore W2994696359C2780835546 @default.
- W2994696359 hasConceptScore W2994696359C2781190966 @default.
- W2994696359 hasConceptScore W2994696359C2781451048 @default.
- W2994696359 hasConceptScore W2994696359C526805850 @default.
- W2994696359 hasConceptScore W2994696359C530470458 @default.
- W2994696359 hasConceptScore W2994696359C71924100 @default.
- W2994696359 hasLocation W29946963591 @default.
- W2994696359 hasOpenAccess W2994696359 @default.
- W2994696359 hasPrimaryLocation W29946963591 @default.
- W2994696359 hasRelatedWork W2073443344 @default.
- W2994696359 hasRelatedWork W2081876561 @default.
- W2994696359 hasRelatedWork W2092802204 @default.
- W2994696359 hasRelatedWork W2095704084 @default.
- W2994696359 hasRelatedWork W2111633398 @default.
- W2994696359 hasRelatedWork W2740803632 @default.
- W2994696359 hasRelatedWork W2767256081 @default.
- W2994696359 hasRelatedWork W2796100748 @default.
- W2994696359 hasRelatedWork W3089122812 @default.
- W2994696359 hasRelatedWork W3139237627 @default.
- W2994696359 hasVolume "22" @default.
- W2994696359 isParatext "false" @default.
- W2994696359 isRetracted "false" @default.
- W2994696359 magId "2994696359" @default.
- W2994696359 workType "article" @default.